SEARCH:   Advanced

Blood, 15 June 2004, Vol. 103, No. 12, pp. 4449-4456. Prepublished online as a Blood First Edition Paper on February 19, 2004; DOI 10.1182/blood-2003-06-1825. This Article Full Text (PDF) All Versions of this Article: 2003-06-1825v1 103/12/4449    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Liu, Y. J. Articles by Han, Z. C. Search for Related Content PubMed PubMed Citation Articles by Liu, Y. J. Articles by Han, Z. C. Social Bookmarking                   What's this? Submitted June 9, 2003 Accepted February 4, 2004 Hemangiopoietin, a novel human growth factor for the primitive cells of both hematopoietic and endothelial cell lineages Yong Jun Liu, Shi Hong Lu, Bin Xu, Ren Chi Yang, Qian Ren, Bin Liu, Bin Li, Min Lu, Feng Ying Yan, Zhi Bo Han, and Zhong Chao Han* State Key Laboratory of Experimental Hematology, Institute of Hematology, CAMS & PUMC, Tianjin, Tianjin, China Union Stem Cell & Gene Engineering Co. Ltd, Tianjin, Tianjin, China * Corresponding author; email: tihzchan{at}public.tpt.tj.cn. The cells of hematopoietic and vascular endothelial cell lineages are believed to share a common precursor, termed hemangioblast. However, the existence of a growth factor acting relatively specifically on hemangioblasts remains unclear. Here we report the identification of hemangiopoietin (HAPO), a novel growth factor acting on both hematopoietic and endothelial cell lineages. In vitro in human system, recombinant human HAPO (rhHAPO) significantly stimulated the proliferation and hematopoietic and/or endothelial differentiation of human bone marrow mononuclear cells, purified CD34+, CD133+, KDR+ or CD34+/KAR+ cell populations. In murine system, rhHAPO stimulated the proliferation of long-term culture-initiating cells (LTC-IC) as well as CD34+ and Sca-1+ cell subsets. In vivo, subcutaneous injection of rhHAPO into normal mice resulted in a significant increase in bone marrow hematopoietic cells. Furthermore, irradiated mice injected with rhHAPO had an enhanced survival rate and accelerated hematopoiesis. Our data demonstrate for the first time that HAPO is a novel growth factor acting on the primitive cells of both hematopoietic and endothelial cell lineages and suggest a clinical potential of HAPO in the treatment of various cytopenias and radiation injury and in the expansion of hematopoietic and endothelial stem/progenitor cells. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: H. Piccard, P. E. Van den Steen, and G. Opdenakker Hemopexin domains as multifunctional liganding modules in matrix metalloproteinases and other proteins J. Leukoc. Biol., April 1, 2007; 81(4): 870 - 892. [Abstract] [Full Text] [PDF] D. K. Rhee, J. Marcelino, S. Al-Mayouf, D. K. Schelling, C. F. Bartels, Y. Cui, R. Laxer, R. Goldbach-Mansky, and M. L. Warman Consequences of Disease-causing Mutations on Lubricin Protein Synthesis, Secretion, and Post-translational Processing J. Biol. Chem., September 2, 2005; 280(35): 31325 - 31332. [Abstract] [Full Text] [PDF] C. Menier, M. Rabreau, J.-C. Challier, M. Le Discorde, E. D. Carosella, and N. Rouas-Freiss Erythroblasts secrete the nonclassical HLA-G molecule from primitive to definitive hematopoiesis Blood, November 15, 2004; 104(10): 3153 - 3160. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020